Insider · CIK 0001891107
Daniel Virnich
ceoofficer
Files at STLN (Oncology Institute, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 20, 2024 | STLN Oncology Institute, Inc. | DDisposition to issuer Common stock | -4,750 | $0.14 | $646 | 716,961 | Nov 21, 2024 |
| Nov 20, 2024 | STLN Oncology Institute, Inc. | DDisposition to issuer Common stock | -4,977 | $0.14 | $677 | 711,984 | Nov 21, 2024 |
| Nov 12, 2024 | STLN Oncology Institute, Inc. | JOther Common stock | -78,094 | $0.00 | $0 | 838,853 | Nov 18, 2024 |
| Nov 12, 2024 | STLN Oncology Institute, Inc. | JOther Common stock | -117,142 | $0.00 | $0 | 721,711 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.